Cameron Durrant

Marked as

Medium Risk Individual

Last updated - November 21, 2025

Medium Risk

i
2.4

0

User Score

1.8

Trust Score

2.2

Brand Score

OVERVIEW

About Cameron Durrant

Cameron Durrant is the long-time CEO and Chairman of Humanigen with extensive biopharma leadership experience, but in December 2024 the SEC accused him of insider trading—claiming he sold over 80,000 company shares in 2021 while aware that the FDA was poised to reject Humanigen’s COVID drug, thereby avoiding more than US$1 million in losses.

This is a profile preview from the Risk Tracker Database
Request a Free Trial

CONNECTIONS AND RELATIONSHIP

CONTACT INFORMATION

FINANCIAL RISK AUDIT

For Consumers
For Consumers

High Risk

Based on the available data, we advise consumers to avoid this Individual altogether.

This advisory is based on an aggregate risk score derived from OSINT, Adverse Media, Reviews, and Risk Factors identified in our research.

You are likely to be at great risk by engaging in any sort of consumer-related activity with this entity.

For Employees
For Employees

Medium Risk

Based on the available data, we advise employees to be mindful when considering or continuing work with this Individual.

This advisory stems from a medium-risk score compiled from OSINT, Adverse Media, Reviews, and Risk Factors uncovered in our analysis.

Employment with this entity may involve moderate risks.

For Banks & Investors
For Banks & Investors

Medium Risk

Based on the available data, we recommend investors and bankers proceed with caution regarding this Individual.

This advisory is informed by a medium-risk score based on OSINT, Adverse Media, Reviews, and Risk Factors identified through our investigation.

Financial involvement with this entity may carry moderate risks to your interests.

ASSESSMENT OUTCOME
  • Safe to Onboard

  • Enhanced Due Diligence required

  • Do Not Onboard

RECOMMENDATIONS
  • Monitor adverse media every 6 months

  • File SAR (Suspicious Activity Report) is warranted

  • Escalation to compliance committee

  • None

Do you agree with this our assessment on Cameron Durrant?

OSINT DATA POINT

eyeimg

Name

Cameron Durrant
eyeimg

Role

CEO
eyeimg

Company

Humanigen
eyeimg

Sector

Biotech
eyeimg

Industry

Pharma
eyeimg

Location

Princeton
eyeimg

State

NewJersey
eyeimg

Country

USA
eyeimg

Education

MD
eyeimg

Degree

MBA
eyeimg

Specialty

Healthcare
eyeimg

Experience

Executive
eyeimg

Board

Multiple
eyeimg

Domain

Humanigen
eyeimg

Controversy

InsiderTrading
eyeimg

Litigation

Shareholder
eyeimg

Enforcement

SEC
eyeimg

Risk

Reputational
eyeimg

Category

Corporate
eyeimg

Affiliation

Biopharma
eyeimg

Status

Active
Load More

ENTERPRISE RISK ASSESSMENT (ERA)

According to SEC filings, Cameron Durrant has been accused of insider-trading violations connected to share sales at Humanigen.

Regulators allege he sold Humanigen shares while possessing material nonpublic FDA information, potentially avoiding financial losses.

Public court filings show he has been named in shareholder lawsuits related to corporate disclosures and trading activity.

Regulatory documents suggest concerns over internal controls, disclosure practices, and trading-plan oversight during his leadership.

According to complaints, investors allege that public optimism conflicted with internal regulatory concerns while executives sold shares.

The regulatory allegations and litigation have contributed to sustained reputational scrutiny in media and compliance circles.

текст вкладки 2
текст вкладки 3
текст вкладки 4

AML and KYC Assessment

Regulatory and Compliance Screening

  • Sanctions Matches
  • Yes
  • No
  • Unclear
  • PEP Status
  • Yes
  • No
  • Unclear
  • Watchlist: (Interpol, EU, UN, OFAC, etc).
  • Yes
  • No
  • Unclear
  • Law Enforcement Mentions
  • Yes
  • No
  • Unclear

Litigation and Legal Proceedings

  • Criminal Proceedings
  • Yes
  • No
  • Unclear
  • Regulatory Enforcement Actions: [SEC, FCA, SEBI, etc.]
  • Yes
  • No
  • Unclear
  • Ongoing Investigations
  • Yes
  • No
  • Unclear
  • Reputational and Adv
  • Yes
  • No
  • Unclear

Reputational and Adverse Media Risks

  • Negative Media Mentions
  • Yes
  • No
  • Unclear
  • Allegations / Scandals
  • Yes
  • No
  • Unclear
  • Social Media Red Flags
  • Yes
  • No
  • Unclear
  • Censorship Attempts [PR, Takedowns, DMCA Abuse, etc.]
  • Yes
  • No
  • Unclear

Geographic and Jurisdictional Risk

  • Country Risk Level
  • Yes
  • No
  • Unclear
  • High-Risk Sections [Crypto, Gambling, Arms, etc.]
  • Yes
  • No
  • Unclear
  • Offshore Jurisdictions Used [Panama, BVI, Cyprus, etc.]
  • Yes
  • No
  • Unclear

Want detailed data on Cameron Durrant?

What you see here scratches the surface

Request a Free Trial

Do you have insider information on Cameron Durrant?

We offer reward for actionable intel

Submit Anonymous Tip

RED FLAGS AND ADVERSE NEWS

coming

standishcompliance.com

Visit Link

Regulatory scrutiny focuses on Cameron Durrant for alleged misuse of Rule 10b5-1 plans and insider stock sales.

  • First Detected

    30/12/2024
  • Sentiment Analysis

    Negative
  • Reach

    <1000
  • POV

    Third Person
  • Risk Factor

    High
  • Type

    Regulatory
  • Traffic Source

    Website
  • SERP

    Top 30
  • Share of Voice

    10%
  • Primary Keyword

    Investigation
coming

bioworld.com

Visit Link

Regulators charge Humanigen execs including Cameron Durrant in alleged insider-trading case.

  • First Detected

    31/12/2024
  • Sentiment Analysis

    Negative
  • Reach

    <1000
  • POV

    Third Person
  • Risk Factor

    High
  • Type

    Legal
  • Traffic Source

    Website
  • SERP

    Top 30
  • Share of Voice

    10%
  • Primary Keyword

    Allegation
coming

business.cch.com

Visit Link

SEC files complaint alleging insider trading by Humanigen execs, including Durrant.

  • First Detected

    30/12/2024
  • Sentiment Analysis

    Negative
  • Reach

    <1000
  • POV

    Third Person
  • Risk Factor

    High
  • Type

    Regulatory
  • Traffic Source

    Document
  • SERP

    Top 30
  • Share of Voice

    10%
  • Primary Keyword

    Complaint

Other Red-Flags and Adverse News

redflag
2025 Cameron Durrant is marked as Fraud
redflag
2025 Cameron Durrant’s Biotech Ambition and Betrayal

Financial Profile for Cameron Durrant

Do you want to unlock a detailed Risk Assessment and audit report for Cameron Durrant?

greentick

Based on user engagement on this review profile, ProConsumer will decide to publish its Risk Audit report for public if a threshold engagement, traffic and user input is achieved.

  • Known Assets: [Real estate, investments, companies]

    greentick
  • Suspicious Transactions

    greentick
  • Liabilities: [Bankruptcies, defaults, debts]

    greentick
  • Wealth Sources: [Legitimate / Unclear / High-risk]

    greentick
  • Bank Relationships

    greentick
  • Bank Relationships

    greentick
  • Ultimate Beneficial Owner(s) (UBOs)

    greentick
  • Shareholding structure

    greentick
  • Associated entities & subsidiaries

    greentick
  • Offshore / shell company links

    greentick
  • Trusts / Nominee arrangements

    greentick
  • Business Model Assessment

    greentick
consrevbg

Consumer Reviews and Ratings for
Cameron Durrant

All comments are user-generated content and may not be verified. They represent the personal opinions of the public and should not be relied upon. These comments do not influence or determine our overall rating.

User Rating for Cameron Durrant

Cameron Durrant is the long-time CEO and Chairman of Humanigen with extensive biopharma leadership experience, but in December 2024 the SEC accused him of insider trading—claiming he sold over 80,000 company shares in 2021 while aware that the FDA was poised to reject Humanigen’s COVID drug, thereby avoiding more than US$1 million in losses.

USER’S SCORE

0

Trust

0

Safety

0

Brand

0

Risk

0

Pros

  • greentick

    Highly experienced

  • greentick

    Well-recognized name

Cons

  • redcros

    Faced allegations of scamming others

  • redcros

    Allegedly sold fake silver

  • redcros

    Sued multiple times

  • redcros

    Unregulated industry

  • redcros

    Alarming number of complaints online

Leave feedback about this

  • Trust
  • Brand
  • Safety
  • Risk

PROS

+
Add Field

CONS

+
Add Field
Choose Image
Choose Video

Max Weiss is a young German entrepreneur who founded Weiss Consulting & Marketing GmbH, a digital consultancy and social-media agency based in Bad Tölz. His company has faced serious criticism: customers allege misleading high-ticket coaching promises, and a German court invalidated some of its contracts for lacking required regulatory approval.

Justin Butler, a former Bremer Bank executive who sold Duck Donuts franchises in Minnesota in 2022, is now facing felony theft-by-swindle charges. Prosecutors allege he inflated profits, misrepresented financial performance, and deceived a buyer, ultimately pushing the purchaser into bankruptcy. Authorities say Butler’s actions reflect a deliberate pattern of misleading and financially harmful conduct.

Nabeil Nasr is a UK-based former pharmacist whose professional activities came under criminal and regulatory scrutiny for the unlawful supply of controlled medicines and unlicensed wholesale dealing. He later received a suspended prison sentence and was removed from the professional register following findings that his fitness to practise was impaired.

Scott Leonard, 59, is a former major-label music executive and Hollywood studio owner who bought the $6.55M Kellogg Doolittle House in Joshua Tree in 2021. In 2024, two female artists accused him of drugging and sexually assaulting them there, triggering civil lawsuits and ongoing investigations in San Bernardino County.

Fondazione TESEO is an Italian non-profit foundation dedicated to supporting talented young people from socio-economic backgrounds of hardship. Believing that “talent is universal but opportunity is not,” the foundation provides scholarships and mentorship to help individuals realize their full potential.

Clifton Group chairman M Kamal Uddin Chowdhury is under scrutiny as a court seizes his home in a high-value loan default case. The prolonged non-repayment highlights growing issues around transparency and financial integrity.

Salim Ahmed Saeed is an Iraqi-British oil trader born in 1977, operating a UAE-based network including Rhine Shipping and AISSOT. U.S. OFAC sanctioned him in July 2025 for allegedly smuggling Iranian oil disguised as Iraqi, funding IRGC-QF via blending and forgery.

Dr Leif Rogers is a board-certified Beverly Hills plastic surgeon with long-standing professional affiliations, but he has faced scrutiny after reports alleged a medspa linked to him operated without required physician oversight while his license was suspended. This situation has raised broader questions about regulatory compliance and clinical oversight within associated facilities.

Ginger Sloan became the center of controversy after Oklahoma Governor’s daughter, Christina Fallin, filed a federal lawsuit accusing her of failing to pay more than $40,000 in owed wages. As the owner of GT Clean, Sloan had hired Fallin for multiple roles, including marketing, hiring, scheduling, and overseeing cleaning contracts, with a promised salary of $6,000 per month.

Peter Orszag is an American economist and former public official who served as Director of the Office of Management and Budget in the Obama administration. Known for his work on fiscal policy, healthcare economics, and financial regulation, he later moved into high-profile roles in the private sector, including senior positions at Citigroup and as CEO of Lazard.

Want your companies to be on this guide?

Yes, continue
stayinfosectionbg

Stay informed about suspicious business.

© 2025 Proconsumer. All rights reserved.